Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...

Sihuan Pharma Gains OK for Opioid Inhibitor

publication date: Jan 16, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sihuan Pharmaceutical Holdings received SFDA approval to begin producing Nalmefene Hydrochloride, a generic version of the “next generation” opioid receptor inhibitor Naloxone/Naltrexone. Nalmefene hydrochloride is used to counteract opioid overdose and to protect from drug relapse. Sihuan said the drug is also effective for treating heart failure, spinal cord injuries and cerebral protection following stroke. Sihuan Pharma specializes in cardio-cerebral vascular drugs. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Investor Forum
2013-Shanhai
September 4-5,2013
Shanghai, China

ChinaBio® Leadership Retraet
2013-Suzhou
October 24-25, 2013
Suzhou, China

ChinaBio® Investor Forum
2013-Wuhan
December 4-5,2013
Wuhan, China
>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

China Forum 2013
November 3, 2013
Vienna, Austria

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners